185 related articles for article (PubMed ID: 23365135)
1. CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma.
Ooi A; Dykema K; Ansari A; Petillo D; Snider J; Kahnoski R; Anema J; Craig D; Carpten J; Teh BT; Furge KA
Cancer Res; 2013 Apr; 73(7):2044-51. PubMed ID: 23365135
[TBL] [Abstract][Full Text] [Related]
2. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma.
Ooi A; Wong JC; Petillo D; Roossien D; Perrier-Trudova V; Whitten D; Min BW; Tan MH; Zhang Z; Yang XJ; Zhou M; Gardie B; Molinié V; Richard S; Tan PH; Teh BT; Furge KA
Cancer Cell; 2011 Oct; 20(4):511-23. PubMed ID: 22014576
[TBL] [Abstract][Full Text] [Related]
3. Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer.
Namani A; Matiur Rahaman M; Chen M; Tang X
BMC Cancer; 2018 Jan; 18(1):46. PubMed ID: 29306329
[TBL] [Abstract][Full Text] [Related]
4. Keap1/Nrf2 pathway in kidney cancer: frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma.
Fabrizio FP; Costantini M; Copetti M; la Torre A; Sparaneo A; Fontana A; Poeta L; Gallucci M; Sentinelli S; Graziano P; Parente P; Pompeo V; De Salvo L; Simone G; Papalia R; Picardo F; Balsamo T; Flammia GP; Trombetta D; Pantalone A; Kok K; Paranita F; Muscarella LA; Fazio VM
Oncotarget; 2017 Feb; 8(7):11187-11198. PubMed ID: 28061437
[TBL] [Abstract][Full Text] [Related]
5. Fumarate hydratase inactivation in renal tumors: HIF1α, NRF2, and "cryptic targets" of transcription factors.
Ooi A; Furge KA
Chin J Cancer; 2012 Sep; 31(9):413-20. PubMed ID: 22776233
[TBL] [Abstract][Full Text] [Related]
6. Nrf2 gene mutation and single nucleotide polymorphism rs6721961 of the Nrf2 promoter region in renal cell cancer.
Yamaguchi Y; Kamai T; Higashi S; Murakami S; Arai K; Shirataki H; Yoshida KI
BMC Cancer; 2019 Nov; 19(1):1137. PubMed ID: 31752777
[TBL] [Abstract][Full Text] [Related]
7. Unique pattern of component gene disruption in the NRF2 inhibitor KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex in serous ovarian cancer.
Martinez VD; Vucic EA; Thu KL; Pikor LA; Hubaux R; Lam WL
Biomed Res Int; 2014; 2014():159459. PubMed ID: 25114896
[TBL] [Abstract][Full Text] [Related]
8. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy.
Shibata T; Ohta T; Tong KI; Kokubu A; Odogawa R; Tsuta K; Asamura H; Yamamoto M; Hirohashi S
Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13568-73. PubMed ID: 18757741
[TBL] [Abstract][Full Text] [Related]
9. Putative chemopreventive molecules can increase Nrf2-regulated cell defense in some human cancer cell lines, resulting in resistance to common cytotoxic therapies.
Hu L; Miao W; Loignon M; Kandouz M; Batist G
Cancer Chemother Pharmacol; 2010 Aug; 66(3):467-74. PubMed ID: 19940992
[TBL] [Abstract][Full Text] [Related]
10. Sustained NRF2 activation in hereditary leiomyomatosis and renal cell cancer (HLRCC) and in hereditary tyrosinemia type 1 (HT1).
Sandhu IS; Maksim NJ; Amouzougan EA; Gallion BW; Raviele AL; Ooi A
Biochem Soc Trans; 2015 Aug; 43(4):650-6. PubMed ID: 26551707
[TBL] [Abstract][Full Text] [Related]
11. Fumarate Hydratase-deficient Cell Line NCCFH1 as a New In Vitro Model of Hereditary Papillary Renal Cell Carcinoma Type 2.
Perrier-Trudova V; Huimin BW; Kongpetch S; Huang D; Ong P; Le Formal A; Poon SL; Siew EY; Myint SS; Gad S; Gardie B; Couvé S; Foong YM; Choudhury Y; Poh J; Ong CK; Toh CK; Ooi A; Richard S; Tan MH; Teh BT
Anticancer Res; 2015 Dec; 35(12):6639-53. PubMed ID: 26637880
[TBL] [Abstract][Full Text] [Related]
12. Frequent concerted genetic mechanisms disrupt multiple components of the NRF2 inhibitor KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex in thyroid cancer.
Martinez VD; Vucic EA; Pikor LA; Thu KL; Hubaux R; Lam WL
Mol Cancer; 2013 Oct; 12(1):124. PubMed ID: 24138990
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma.
; Linehan WM; Spellman PT; Ricketts CJ; Creighton CJ; Fei SS; Davis C; Wheeler DA; Murray BA; Schmidt L; Vocke CD; Peto M; Al Mamun AA; Shinbrot E; Sethi A; Brooks S; Rathmell WK; Brooks AN; Hoadley KA; Robertson AG; Brooks D; Bowlby R; Sadeghi S; Shen H; Weisenberger DJ; Bootwalla M; Baylin SB; Laird PW; Cherniack AD; Saksena G; Haake S; Li J; Liang H; Lu Y; Mills GB; Akbani R; Leiserson MD; Raphael BJ; Anur P; Bottaro D; Albiges L; Barnabas N; Choueiri TK; Czerniak B; Godwin AK; Hakimi AA; Ho TH; Hsieh J; Ittmann M; Kim WY; Krishnan B; Merino MJ; Mills Shaw KR; Reuter VE; Reznik E; Shelley CS; Shuch B; Signoretti S; Srinivasan R; Tamboli P; Thomas G; Tickoo S; Burnett K; Crain D; Gardner J; Lau K; Mallery D; Morris S; Paulauskis JD; Penny RJ; Shelton C; Shelton WT; Sherman M; Thompson E; Yena P; Avedon MT; Bowen J; Gastier-Foster JM; Gerken M; Leraas KM; Lichtenberg TM; Ramirez NC; Santos T; Wise L; Zmuda E; Demchok JA; Felau I; Hutter CM; Sheth M; Sofia HJ; Tarnuzzer R; Wang Z; Yang L; Zenklusen JC; Zhang J; Ayala B; Baboud J; Chudamani S; Liu J; Lolla L; Naresh R; Pihl T; Sun Q; Wan Y; Wu Y; Ally A; Balasundaram M; Balu S; Beroukhim R; Bodenheimer T; Buhay C; Butterfield YS; Carlsen R; Carter SL; Chao H; Chuah E; Clarke A; Covington KR; Dahdouli M; Dewal N; Dhalla N; Doddapaneni HV; Drummond JA; Gabriel SB; Gibbs RA; Guin R; Hale W; Hawes A; Hayes DN; Holt RA; Hoyle AP; Jefferys SR; Jones SJ; Jones CD; Kalra D; Kovar C; Lewis L; Li J; Ma Y; Marra MA; Mayo M; Meng S; Meyerson M; Mieczkowski PA; Moore RA; Morton D; Mose LE; Mungall AJ; Muzny D; Parker JS; Perou CM; Roach J; Schein JE; Schumacher SE; Shi Y; Simons JV; Sipahimalani P; Skelly T; Soloway MG; Sougnez C; Tam A; Tan D; Thiessen N; Veluvolu U; Wang M; Wilkerson MD; Wong T; Wu J; Xi L; Zhou J; Bedford J; Chen F; Fu Y; Gerstein M; Haussler D; Kasaian K; Lai P; Ling S; Radenbaugh A; Van Den Berg D; Weinstein JN; Zhu J; Albert M; Alexopoulou I; Andersen JJ; Auman JT; Bartlett J; Bastacky S; Bergsten J; Blute ML; Boice L; Bollag RJ; Boyd J; Castle E; Chen YB; Cheville JC; Curley E; Davies B; DeVolk A; Dhir R; Dike L; Eckman J; Engel J; Harr J; Hrebinko R; Huang M; Huelsenbeck-Dill L; Iacocca M; Jacobs B; Lobis M; Maranchie JK; McMeekin S; Myers J; Nelson J; Parfitt J; Parwani A; Petrelli N; Rabeno B; Roy S; Salner AL; Slaton J; Stanton M; Thompson RH; Thorne L; Tucker K; Weinberger PM; Winemiller C; Zach LA; Zuna R
N Engl J Med; 2016 Jan; 374(2):135-45. PubMed ID: 26536169
[TBL] [Abstract][Full Text] [Related]
14. Fumarate Mediates a Chronic Proliferative Signal in Fumarate Hydratase-Inactivated Cancer Cells by Increasing Transcription and Translation of Ferritin Genes.
Kerins MJ; Vashisht AA; Liang BX; Duckworth SJ; Praslicka BJ; Wohlschlegel JA; Ooi A
Mol Cell Biol; 2017 Jun; 37(11):. PubMed ID: 28289076
[TBL] [Abstract][Full Text] [Related]
15. Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway.
Hayes JD; McMahon M; Chowdhry S; Dinkova-Kostova AT
Antioxid Redox Signal; 2010 Dec; 13(11):1713-48. PubMed ID: 20446772
[TBL] [Abstract][Full Text] [Related]
16. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer.
Hayes JD; McMahon M
Trends Biochem Sci; 2009 Apr; 34(4):176-88. PubMed ID: 19321346
[TBL] [Abstract][Full Text] [Related]
17. Disruption of CUL3-mediated ubiquitination causes proximal tubule injury and kidney fibrosis.
Saritas T; Cuevas CA; Ferdaus MZ; Kuppe C; Kramann R; Moeller MJ; Floege J; Singer JD; McCormick JA
Sci Rep; 2019 Mar; 9(1):4596. PubMed ID: 30872636
[TBL] [Abstract][Full Text] [Related]
18. The Keap1-Nrf2 system as an in vivo sensor for electrophiles.
Uruno A; Motohashi H
Nitric Oxide; 2011 Aug; 25(2):153-60. PubMed ID: 21385624
[TBL] [Abstract][Full Text] [Related]
19. Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.
Ghosh AP; Marshall CB; Coric T; Shim EH; Kirkman R; Ballestas ME; Ikura M; Bjornsti MA; Sudarshan S
Oncotarget; 2015 Jul; 6(20):17895-910. PubMed ID: 26255626
[TBL] [Abstract][Full Text] [Related]
20. Impacts of NRF2 activation in non-small-cell lung cancer cell lines on extracellular metabolites.
Saigusa D; Motoike IN; Saito S; Zorzi M; Aoki Y; Kitamura H; Suzuki M; Katsuoka F; Ishii H; Kinoshita K; Motohashi H; Yamamoto M
Cancer Sci; 2020 Feb; 111(2):667-678. PubMed ID: 31828882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
